Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Engineering MicroMod CAR T-Cells To Overcome the Immunosuppressive Microenvironment in Myeloma

EF 2020-21

Résumé
Multiple myeloma (MM) is a malignant disease of immune cells called plasma cells characterized by immune suppression, bone lesions, and kidney failure. MM accounts for 12% of all new blood cancer diagnoses in Canada, with over 3300 Canadians diagnosed per year. Recent treatment advancements have prolonged survival; however, essentially all patients suffer multiple relapses and succumb to disease progression. Chimeric antigen receptor (CAR) T-cell therapy is a new approach that involves harnessing the patient's own immune cells, called T-cells, and re-engineering them to seek out and destroy tumour cells. While this immunotherapy approach has shown success in other blood cancers, CAR T-cell therapy has only produced mild responses in MM with a high incidence of relapse. Recent evidence points towards the MM tumour microenvironment (TME), the compartment where the MM cells are located, as a potential factor in CAR T-cell failure. The TME contains a mixed cell population that supports MM growth. In particular, MM cells have been shown to polarize certain immune cells towards a MM-supporting role. These cells have been shown to protect MM cells from chemotherapy and immunotherapy. Recent findings have found that engineering CAR T-cells to secrete pro-immune molecules such as IL-12, or to remove certain molecules such as IL-6 can modulate the TME. By engineering MicroMod CAR T-cells to secrete IL-12 and remove IL-6, I aim to create a more pro-immune TME to achieve more durable responses following CAR T-cell therapy in MM. The results from this study will inform future CAR T-cell studies and contribute towards developing new treatments for this population of patients that desperately needs new therapeutic options.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
449306
Name
Lindo Lorenzo
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Engineering MicroMod CAR T-Cells To Overcome the Immunosuppressive Microenvironment in Myeloma
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Car T-Cells; Chimeric Antigen Receptors; Hematology; Immunology; Immunotherapy; Macrophages; Multiple Myeloma; Oncology; Tumour Microenvironment
Abstract
Multiple myeloma (MM) is a malignant disease of immune cells called plasma cells characterized by immune suppression, bone lesions, and kidney failure. MM accounts for 12% of all new blood cancer diagnoses in Canada, with over 3300 Canadians diagnosed per year. Recent treatment advancements have prolonged survival; however, essentially all patients suffer multiple relapses and succumb to disease progression. Chimeric antigen receptor (CAR) T-cell therapy is a new approach that involves harnessing the patient's own immune cells, called T-cells, and re-engineering them to seek out and destroy tumour cells. While this immunotherapy approach has shown success in other blood cancers, CAR T-cell therapy has only produced mild responses in MM with a high incidence of relapse. Recent evidence points towards the MM tumour microenvironment (TME), the compartment where the MM cells are located, as a potential factor in CAR T-cell failure. The TME contains a mixed cell population that supports MM growth. In particular, MM cells have been shown to polarize certain immune cells towards a MM-supporting role. These cells have been shown to protect MM cells from chemotherapy and immunotherapy. Recent findings have found that engineering CAR T-cells to secrete pro-immune molecules such as IL-12, or to remove certain molecules such as IL-6 can modulate the TME. By engineering MicroMod CAR T-cells to secrete IL-12 and remove IL-6, I aim to create a more pro-immune TME to achieve more durable responses following CAR T-cell therapy in MM. The results from this study will inform future CAR T-cell studies and contribute towards developing new treatments for this population of patients that desperately needs new therapeutic options.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lindo, Lorenzo
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~